The bacteriophage therapy was recently utilized for a patient in Western Canada with a periprosthetic joint infection. The approach offered a targeted alternative to conventional treatments that often rely on prolonged antibiotic use and expensive surgeries. It proved to address the clinical challenges of antimicrobial-resistant infections’ drug resistance while providing a cost-effective solution by reducing hospital stays, surgical interventions, and reliance on imported, non-domestically approved antibiotics.

Qeen Biotechnologies’ innovation is particularly significant as antimicrobial-resistant infections pose growing threats to global health, often leading to life-altering consequences such as amputations or fatalities when standard treatments fail. Qeen’s precision-engineered phages specifically target harmful bacteria, presenting a personalized and scalable solution for complex infections. By adhering to GMP standards, the company sets a high benchmark in bacteriophage manufacturing, ensuring the safety and effectiveness of its therapies.

Image Credit: Qeen Biotechnologies